ReShape Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ReShape Lifesciences
RSLS Stock  USD 2.33  0.07  2.92%   
ReShape Lifesciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ReShape Lifesciences' valuation are provided below:
Gross Profit
4.6 M
Profit Margin
(0.48)
Market Capitalization
5.9 M
Enterprise Value Revenue
0.4923
Revenue
7.2 M
There are over one hundred nineteen available trending fundamental ratios for ReShape Lifesciences, which can be analyzed over time and compared to other ratios. All traders should check out ReShape Lifesciences' recent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 78.1 M in 2025. Enterprise Value is likely to drop to about 74.1 M in 2025

ReShape Lifesciences Total Revenue

5.62 Million

Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26 M or Total Operating Expenses of 11.1 M, as well as many indicators such as Price To Sales Ratio of 6.82, Dividend Yield of 0.0 or Days Sales Outstanding of 42.75. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
  
Build AI portfolio with ReShape Stock
Check out the analysis of ReShape Lifesciences Correlation against competitors.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

ReShape Lifesciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.6 M4.8 M26 M
Very volatile
Other Assets111.4 K117.3 K2.9 M
Very volatile
Common Stock Shares Outstanding541.3 K515.6 K148.6 K
Pretty Stable
Liabilities And Stockholders Equity4.6 M4.8 M26 M
Very volatile
Other Stockholder Equity341.1 M642.6 M389.3 M
Slightly volatile
Total Liabilities4.8 M5 M9.6 M
Pretty Stable
Short and Long Term Debt Total918.6 K967 K4.1 M
Slightly volatile
Total Current Liabilities6 M5 M5.6 M
Pretty Stable
Property Plant And Equipment Net146.3 K154 K562.1 K
Very volatile
Accounts Payable1.3 M2.2 M1.5 M
Slightly volatile
Cash658.4 K693 K10.1 M
Slightly volatile
Non Current Assets Total194.8 K205 K12.8 M
Very volatile
Non Currrent Assets Other31.7 K33.4 K517.5 K
Slightly volatile
Cash And Short Term Investments658.4 K693 K10.2 M
Slightly volatile
Net Receivables1 M987 K1.1 M
Slightly volatile
Common Stock Total Equity6.6 K6.9 K166.4 K
Slightly volatile
Non Current Liabilities Total58 K61 K4.8 M
Slightly volatile
Other Current Assets817 K448 K805.4 K
Pretty Stable
Property Plant And Equipment Gross252.7 K266 K602 K
Pretty Stable
Total Current Assets4.4 M4.6 M13.9 M
Slightly volatile
Short Term Debt879.7 K926 K2 M
Slightly volatile
Common Stock19 K20 K169.6 K
Slightly volatile
Property Plant Equipment565.6 K782.1 K586 K
Pretty Stable
Other Liabilities934.1 K983.2 K2.3 M
Pretty Stable
Long Term Debt Total11.1 M10.5 M5.5 M
Slightly volatile
Capital Surpluse386.1 M608.8 M387.3 M
Slightly volatile
Short and Long Term Debt693.4 K729.9 K2.3 M
Slightly volatile
Non Current Liabilities Other933.4 K1.1 M1.7 M
Slightly volatile
Net Invested Capital530.1 K558 K46.2 M
Slightly volatile
Capital Lease Obligations281.7 K156 K581.7 K
Slightly volatile

ReShape Lifesciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses26 M14.7 M25.5 M
Slightly volatile
Depreciation And Amortization168.2 K177.1 K594.6 K
Slightly volatile
Selling General Administrative13.7 M6.9 M14.9 M
Very volatile
Research Development1.7 M1.8 M6.3 M
Slightly volatile
Interest Income12.9 K14 K14.1 K
Slightly volatile
Reconciled Depreciation20.9 K22 K1 M
Very volatile
Selling And Marketing Expenses2.8 M3 M5.8 M
Pretty Stable
Non Recurring8.8 M7.3 M11.4 M
Slightly volatile

ReShape Lifesciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4.3 M4.6 M11.9 M
Slightly volatile
Depreciation20.9 K22 K651.6 K
Slightly volatile
Total Cash From Financing Activities643.1 K677 K16.1 M
Pretty Stable
End Period Cash Flow753.4 K793 K10.1 M
Slightly volatile
Stock Based Compensation174.8 K184 K3.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.827.1803271.6 K
Slightly volatile
Days Sales Outstanding42.7544.9981103
Very volatile
Average Payables1.3 M1.2 M986.5 K
Slightly volatile
Stock Based Compensation To Revenue0.02180.0237.8082
Slightly volatile
Capex To Depreciation0.310.320.5698
Slightly volatile
EV To Sales6.857.2145271.6 K
Slightly volatile
Inventory Turnover0.921.19880.88
Slightly volatile
Days Of Inventory On Hand2893041.7 K
Slightly volatile
Payables Turnover0.91.33561.0098
Slightly volatile
Sales General And Administrative To Revenue0.820.865712.595
Slightly volatile
Research And Ddevelopement To Revenue0.210.225213.0217
Slightly volatile
Capex To Revenue0.00540.00570.0893
Slightly volatile
Cash Per Share1.281.344243.3 K
Slightly volatile
Days Payables Outstanding260273620
Pretty Stable
Income Quality0.830.62090.7265
Pretty Stable
Intangibles To Total Assets0.02550.02680.5842
Slightly volatile
Current Ratio0.870.920415.2675
Pretty Stable
Receivables Turnover8.528.11145.1
Pretty Stable
Capex Per Share0.460.48352
Slightly volatile
Average Receivables664.2 K632.5 K490.8 K
Slightly volatile
Revenue Per Share14.7515.52863.3 K
Very volatile
Interest Debt Per Share1.781.875613.8 K
Slightly volatile
Debt To Assets0.20.20180.1544
Slightly volatile
Operating Cycle3323491.8 K
Slightly volatile
Days Of Payables Outstanding260273620
Pretty Stable
Ebt Per Ebit1.071.06341.4088
Pretty Stable
Long Term Debt To Capitalization0.340.450.3549
Very volatile
Total Debt To Capitalization1.421.35430.3433
Pretty Stable
Quick Ratio0.410.426914.2015
Pretty Stable
Net Income Per E B T1.191.00551.0573
Pretty Stable
Cash Ratio0.130.13913.5941
Slightly volatile
Days Of Inventory Outstanding2893041.7 K
Slightly volatile
Days Of Sales Outstanding42.7544.9981103
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0272
Slightly volatile
Fixed Asset Turnover54.5951.98712.8933
Slightly volatile
Debt Ratio0.20.20180.1544
Slightly volatile
Price Sales Ratio6.827.1803271.6 K
Slightly volatile
Asset Turnover1.751.67040.4019
Slightly volatile
Gross Profit Margin0.430.63170.5018
Slightly volatile

ReShape Lifesciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap78.1 M82.2 M50.7 B
Slightly volatile
Enterprise Value74.1 M78 M50.7 B
Slightly volatile

ReShape Fundamental Market Drivers

Cash And Short Term Investments693 K

ReShape Upcoming Events

23rd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About ReShape Lifesciences Financial Statements

ReShape Lifesciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue50.6 K53.1 K
Total Revenue8 M5.6 M
Cost Of Revenue2.9 M2.3 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.87  0.82 
Research And Ddevelopement To Revenue 0.23  0.21 
Capex To Revenue 0.01  0.01 
Revenue Per Share 15.53  14.75 
Ebit Per Revenue(0.83)(0.87)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY